Attributes | Values |
---|
rdf:type
| |
Description
| - The present study was undertaken to evaluate the effects of chronic treatment with c-AUCB, a novel inhibitor of soluble epoxide hydrolase (sEH) which is responsible for the conversion of biologically active epoxyeicosatrienoic acids to biologically inactive dihydroxyeicosatrienoic acids, on blood pressure and myocardial infarct size in male heterozygous Ren-2 transgenic rats with established hypertension. Our findings indicate that chronic inhibition of sEH exhibits antihypertensive and cardioprotective actions in this transgenic model of angiotensin II-dependent hypertension
- The present study was undertaken to evaluate the effects of chronic treatment with c-AUCB, a novel inhibitor of soluble epoxide hydrolase (sEH) which is responsible for the conversion of biologically active epoxyeicosatrienoic acids to biologically inactive dihydroxyeicosatrienoic acids, on blood pressure and myocardial infarct size in male heterozygous Ren-2 transgenic rats with established hypertension. Our findings indicate that chronic inhibition of sEH exhibits antihypertensive and cardioprotective actions in this transgenic model of angiotensin II-dependent hypertension (en)
|
Title
| - Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension
- Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension (en)
|
skos:prefLabel
| - Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension
- Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension (en)
|
skos:notation
| - RIV/67985823:_____/12:00377329!RIV13-AV0-67985823
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - I, P(1M0510), P(IAAX01110901), P(KAN200520703), P(NS10499), P(NS9699), P(NS9703), Z(AV0Z50110509)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/67985823:_____/12:00377329
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - hypertension; angiotensin II; kidney; epoxyeicosatrienoic acids; soluble epoxide hydrolase inhibitor; myocardial ischemia/reperfusion injury (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Neckář, Jan
- Kolář, František
- Malý, J.
- Červenka, L.
- Papoušek, František
- Netuka, I.
- Ošťádal, Bohuslav
- Imig, J. D.
- Kramer, H. J.
- Husková, Z.
- Hammock, B. D.
- Hwang, S. H.
- Kopkan, L.
|
http://linked.open...ain/vavai/riv/wos
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| |
is http://linked.open...avai/riv/vysledek
of | |